ACE Report Cover
Subsidence and retroversion of femoral stem not affected by tobramycin-laden bone cement
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos

ARTHROPLASTY

The effect of adding tobramycin to Simplex P cement on femoral stem micromotion as measured by radiostereometric analysis: a 2-year randomized controlled trial
Verified
This report has been verified by one or more authors of the original publication.

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(12):91 Acta Orthop. 2012 Apr;83(2):115-20. doi: 10.3109/17453674.2011.652885. Epub 2012 Jan 17

Autores colaboradores

E Bohm M Petrak T Gascoyne T Turgeon

28 patients scheduled for total hip arthroplasty were randomized to receive cementing of components with simplex P cement or simplex T cement (which is simplex P cement with 1g tobramycin added by the manufacturer), to determine the effect of the antibiotic on aseptic component loosening. Radiostereometric analysis (RSA) of migration and rotation of the femoral stem component and clinical outcomes of Harris Hip and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores were examined over 2 years. The results indicated that there were no significant differences between groups at any time and demonstrated that simplex T cement did not adversely affect component loosening and functional outcomes in total hip arthroplasty over 2 years.


Detalles de la financiación de la publicación +
Financiación:
Industry funded
Patrocinador:
Stryker Orthopaedics
Conflictos:
None disclosed

Riesgo de sesgo

8,5/10

Criterios de información

17/20

Índice de fragilidad

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Sí = 1

Incierto = 0,5

No relevante = 0

No = 0

La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.

4/4

Randomization

4/4

Outcome Measurements

3/4

Inclusion / Exclusion

3/4

Therapy Description

3/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.

¿Por qué se necesitaba ahora este estudio?

Since the introduction of antibiotic-laden bone cement, laboratory testing has shown that a 1 gram to 20 gram ratio of antibiotic to bone cement powder has a negligible effect on the mechanical strength and fixation properties of bone cement. However, the appropriateness of the laboratory testing has been questioned, since regulatory standards require testing after 24 hours, which does not necessarily translate into long-term clinical success. Furthermore, no study has directly examined antibiotic additives to bone cement with the risk of aseptic loosening of components, indicating the need for this trial.

¿Cuál era la pregunta principal de la investigación?

Does Simplex T bone cement increase the risk of aseptic component loosening when measured after 2 years?

Características del estudio +
Población:
28 patients (30 hips) scheduled for primary total hip arthroplasty with Exeter femoral stems coupled with Trident acetabular cups (Stryker Orthopaedics). Direct lateral or posterior surgical approaches were performed. Tantalum markers were injected into greater trochanter, lesser trochanter, and femoral shaft for detection of migration using RSA (n=25 hips completed follow-up)
Intervención:
Simplex T Group: Patients received cementing of components with tobramycin-laden Simplex P bone cement. (n=14)
Comparación:
Simplex P Group: Patients received cementing of components with Simplex P bone cement, with no antibiotic added by the manufacturer. (n=11)
Resultados:
Primary outcome was stem subsidence measured with RSA. Secondary outcomes were stem rotation/retroversion (assessed with RSA) and functional scores (assessed with Harris Hip Score and Western Ontario and McMaster Universities Arthritis Index (WOMAC))
Métodos:
RCT, Triple blind
Tiempo:
Follow-up was conducted at 6 weeks (RSA exclusive), 6 months, 1, and 2 years.

¿Cuáles fueron los hallazgos importantes?

  • Mean subsidence after 2 years did not significantly differ between groups, with translation of 0.71mm (SD 0.30) in the control group (Simplex P) and 0.77mm (SD 0.36) in tobramycin-laden group (Simplex T) (Difference 0.06, 95%CI -0.21 to 0.34, p=0.6). Component translation did not significantly differ between groups at the 6 month (p=0.9) or 1 year (p=0.7) follow-up periods, either.
  • The two groups did not significantly differ in mean retroversion of component after 2 years: 0.60 degrees (SD 0.72) for Simplex P group versus 0.84 degrees (0.93) for Simplex T group (Difference -0.24, 95%CI -0.94 to 0.47, p=0.5). Progression of retroversion at 6 months (p=0.6) and 1 year (p=0.6) follow-up were not significantly different between groups.
  • Differences were not significant between groups in functional outcomes of Harris Hip Scores and WOMAC Scores at any point in the study. (all p-values>0.2).
  • Cumulative migrations in the second year indicated substantial distal and moderate posterior migration of the stem, which was similar in both groups.
¿Qué es lo que más debo recordar?

The addition of tobramycin to Simplex P bone cement had no effect on the subsidence and retroversion of the femoral stem, as well Harris hip and WOMAC functional scores, when compared to bone cement without antibiotic after 2 years.

¿Cómo afectará esto al cuidado de mis pacientes?

The results of this trial indicated that antibiotic-laden bone cement is a safe method of cementing in total hip arthroplasty as it did not affect the subsidence and retroversion of the femoral stem component after 2 years. However, further studies with longer follow-up and larger sample sizes are necessary to assess the long-term results.

DESCARGO DE RESPONSABILIDAD

El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.

0 de 4 artículos mensuales GRATIS desbloqueados
Ha alcanzado su límite de vistas de 4 artículos gratuitos este mes

Acceda a OrtoEvidencia por tan sólo 1,99 $ a la semana.

Manténgase conectado con las últimas pruebas. Cancele en cualquier momento.
  • Valoraciones críticas de los últimos ensayos controlados aleatorizados de gran impacto y revisiones sistemáticas en ortopedia
  • Acceso al contenido del podcast OrthoEvidence, que incluye colaboraciones con el Journal of Bone and Joint Surgery, entrevistas con cirujanos reconocidos internacionalmente y mesas redondas sobre noticias y temas ortopédicos
  • Suscripción a The Pulse, un boletín quincenal basado en la evidencia y diseñado para ayudarle a tomar mejores decisiones clínicas
Upgrade
Close Dialog
Bienvenido
¿Ha olvidado su contraseña?
Comience hoy mismo su prueba GRATUITA

Su cuenta estará afiliada a
e incluye acceso gratuito a OrthoEvidence


O
¿Olvidó su contraseña?

O
Compruebe su correo electrónico

Si existe una cuenta con la dirección de correo electrónico proporcionada, se le enviará un correo electrónico para restablecer la contraseña. Si no ve el correo electrónico, compruebe su carpeta de correo no deseado o spam.

Si necesita más ayuda póngase en contacto con nuestro equipo de asistencia.

Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Traducir Informe ACE

OrthoEvidence utiliza un servicio de traducción de terceros para que el contenido sea accesible en varios idiomas. Tenga en cuenta que, aunque se hace todo lo posible para garantizar la exactitud, las traducciones no siempre son perfectas.

Cómo citar esto ACE Report

OrthoEvidence. Subsidence and retroversion of femoral stem not affected by tobramycin-laden bone cement. OE Journal. 2013;1(12):91. Available from: https://myorthoevidence.com/AceReport/Show/subsidence-and-retroversion-of-femoral-stem-not-affected-by-tobramycin-laden-bone-cement

Copiar cita
Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Función de miembro Premium

Para acceder a esta función, debe iniciar sesión en una cuenta Premium de OrthoEvidence.

Compartir ACE Report